Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2008

View Archived Issues

Long-term benefits and safety of belimumab in SLE

Tapentadol IR demonstrates efficacy and safety in pain clinical studies

Bentley completes spin-off of CPEX and is to be acquired by Teva

Bayer HealthCare acquires Maxygen's hemophilia program assets

ACIP votes to add sanofi pasteur's Pentacel to VFC program

MiddleBrook enters investment agreement to support launch of Moxatag

Recent patents claim novel anticancer agents

Recent patent discloses new hepatoprotectants for liver diseases

RegeneRx receives USD 100,000 award from MIPS for research in cardiac reperfusion injury

FAAH inhibitor AM-3506 shows antihypertensive effects in vivo

Labopharm submits complete response to FDA in relation to appeal process for tramadol

Novel orally inhaled dihydroergotamine for migraine safe in asthmatics

Merck & Co. discloses results from recent clinical studies with telcagepant

Lonza completes acquisition of Amaxa

SkyePharma reports positive results from phase III SKY2028-3-001 clinical trial of Flutiform

Shire to launch a voluntary public takeover offer for shares in Jerini

NIAID and NCRR award SBIR grant to Antigen Discovery for serodiagnostic platform

FDA lifts clinical hold on IND for Adolor and GSK's Entereg in OBD

Akorn and Bioniche enter manufacturing and supply agreement for two injectable products

Evotec reports top-line results from phase Ib dose safety study of EVT-101

Anesiva launches Zingo for pain reduction in i.v. line placements in children

Relistor gains E.U. approval for opioid-induced constipation

Pfizer launches new orally disintegrating formulation of Norvasc in Japan

Recent Wyeth and Curis patent imparts new therapeutic agents for alopecia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...